Recombinant CD38 (Isatuximab Biosimilar) 抗体
The Humanized 单克隆 anti-CD38 (Isatuximab Biosimilar) antibody (ABIN7795129) specifically detects CD38 (Isatuximab Biosimilar) in FACS 和 in vivo.
The antibody is reactive with 人 samples.
产品编号 ABIN7795129
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant CD38 (Isatuximab Biosimilar) 抗体 (ABIN7795129)
抗原
CD38 (Isatuximab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CD38 (Isatuximab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Isatuximab Biosimilar, CD38 Monoclonal Antibody
-
产品特性
- Isatuximab Biosimilar uses the same protein sequences as the therapeutic antibody isatuximab. Isatuximab is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with daratumumab, another anti-CD38 monoclonal antibody, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human CD38
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CD38 (Isatuximab Biosimilar)
-
别名
- Isatuximab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
